ArkBio Finishes Australia Ph1 Dosing of AK0406
Decision brief
Answer first · skim in under a minute
ArkBio said July 23, 2026 that all healthy-volunteer cohorts were dosed in an Australian Phase I trial of influenza AFC candidate AK0406 (NCT07432698).
ArkBio AK0406 Australia Phase 1 influenza AFC dosing is complete across healthy-volunteer cohorts, the Shanghai company said on July 23, 2026. The long-acting antiviral-Fc conjugate study has entered follow-up, with safety and PK still pending public disclosure.
Contents10 sections
Key Takeaways
- All cohorts of healthy volunteers have been dosed in the Australian Phase I trial of AK0406.
- AK0406 is a long-acting antiviral-Fc conjugate designed for influenza prophylaxis.
- Registry NCT07432698 lists single-ascending doses from 150 mg to 900 mg subcutaneously.
- No human safety or PK tables were released with the dosing-complete notice.
AK0406 Phase I at a glance
| Field | Detail |
|---|---|
| Candidate | AK0406 (antiviral-Fc conjugate) |
| Sponsor | Shanghai Ark Biopharmaceutical; Ark Biosciences Pty Ltd |
| Location | Australia (Phase I healthy volunteers) |
| Design | Randomized, double-blind, placebo-controlled, dose escalation |
| Registry | NCT07432698 |
| Dose cohorts | 150 / 300 / 600 / 900 mg subcutaneous |
| Status update | All cohorts dosed; follow-up ongoing (July 23, 2026) |
What did ArkBio announce?
Shanghai Ark Biopharmaceutical said all cohorts of healthy volunteers have been dosed in an Australian Phase I trial of AK0406, a novel long-acting antiviral-Fc conjugate for influenza prophylaxis. The study has entered the follow-up phase. The wire did not include adverse-event rates or PK parameters.
Source: ArkBio's July 23 PR Newswire Phase I dosing-complete release.
What does NCT07432698 specify?
ClinicalTrials.gov lists NCT07432698 as a Phase I, single-center, randomized, double-blind, placebo-controlled first-in-human study of AK0406 injection in healthy adults, sponsored by Shanghai Ark Biopharmaceutical with Australian site participation via Ark Biosciences Pty Ltd. Estimated enrollment is 32 participants across four cohorts.
Source: ClinicalTrials.gov study NCT07432698 for AK0406.
Cohorts escalate from 150 mg to 900 mg subcutaneous single doses with sentinel dosing. Completing all cohort dosing means the escalation ladder finished; it does not mean the database is locked or that prophylactic efficacy was tested — this FIH study evaluates safety, tolerability, and PK only.
Why an antiviral-Fc conjugate for influenza?
ArkBio said AK0406 conjugates potent antivirals to an antibody Fc fragment to prolong exposure, retain Fc effector functions, and cover influenza A and B in preclinical models. The company argues seasonal vaccines face antigenic drift and weaker protection in elderly or immunocompromised groups — a rationale for long-acting prophylaxis, not a clinical proof.
Australian ethics oversight for FIH work typically sits with a Human Research Ethics Committee; broader Australian medicines regulation is handled by the Therapeutic Goods Administration. APAC respiratory pipeline readers can also track vaccine precedents such as Takeda's TAK-003 India dengue approval for regional prevention framing.
- FIH only — no infected-patient efficacy cohort in this announcement
- Dose range 150–900 mg SC per registry
- Follow-up ongoing after July 23 dosing-complete notice
- ArkBio also cites RSV (ziresovir) and IPF (AK3280) respiratory assets
What should developers watch next?
Next catalysts are SAD safety tables, half-life estimates that could support infrequent prophylaxis dosing, and any decision to open patient or challenge studies. If Fc-mediated inflammatory signals appear, dose or schedule may need redesign before Phase II.
Until PK/PD and antiviral activity in humans are published, AK0406 remains a platform FIH milestone for China-origin influenza prevention research conducted under Australian Phase I infrastructure.
What remains unproven?
Human safety, pharmacokinetics, antiviral activity, and prophylactic efficacy are not yet public. Preclinical broad-spectrum claims against influenza A and B cannot be assumed to translate. Pandemic-preparedness positioning is aspirational until clinical data exist.
Related NovaPharma coverage
- Takeda TAK-003 Wins India Dengue Vaccine Nod
- Orasis Files BESKA Presbyopia NDA in Australia
- TGA expands SPEVIGO for adolescent GPP care
Frequently Asked Questions
What milestone did ArkBio report for AK0406?
On July 23, 2026, ArkBio said all healthy-volunteer cohorts have been dosed in an Australian Phase I trial of influenza antiviral-Fc conjugate AK0406 and that the study has entered follow-up.
What is NCT07432698?
It is the ClinicalTrials.gov record for a randomized, double-blind, placebo-controlled Phase I dose-escalation study of AK0406 (150–900 mg SC) in healthy adults, with estimated enrollment of 32.
Does dosing completion mean the drug works against influenza?
No. Phase I healthy-volunteer dosing evaluates safety, tolerability, and pharmacokinetics. No efficacy in infected patients was reported with the July 23 notice.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for AK0406.
Unlock full calendar →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
